Artigos relacionados

Zilurgisertib (Atebrioz)

Approved F.O.P. therapy marketed as Atebrioz; inhibits the ALK2 protein involved in directing bone growth.

• Novos Tratamentos Oferecem Esperança para Pacientes com o Distúrbio Ósseo Descontrolado F.O.P.